Monday 28 November

CIPA Life Science Conference 2022 – Manchester

When and where

Date and time

Start: Monday 28 November 2022, 09:00 AM

End: Tuesday 29 November 2022, 02:00 PM


The Midland Hotel, 16 Peter Street, Manchester, M60 2DS

Event Overview

Important Note: CIPA Life Sciences Conference is now fully booked. If you would like to be added onto the waiting list, please email [email protected]



We are delighted to announce that the CIPA Life Sciences Conference is returning to its normal format and will take place on 28 and 29 November at the Midland Hotel in Manchester.

Up to 9 hours of CPD!

Hotel directions can be found here 

Life Science Conference Dinner:

We are delighted to be able to host a dinner on Monday 28 November after the first day of the conference. A place at the dinner is included in some of the options below and is available to both members and non-members.

The dinner will consist of a 3 course meal, drinks and the opportunity to win a prize!

Conference Prices: please note tickets for the conference are fully booked.

  • Sunday Accommodation: £125.00 +VAT
  • Full Conference: £600.00 +VAT (members), £870.00 +VAT (non-members)
  • Monday – Conference, Dinner and Accommodation: £520.00 +VAT (members)
  • Monday – Accommodation Only: £125.00 +VAT
  • Monday – Conference Only: £300.00 +VAT (members), £400.00 +VAT (non-members)
  • Monday – Dinner Only: £100.00 +VAT (members), £120.00 +VAT (non-members)
  • Tuesday – Conference Only: £145.00 +VAT (members), £215.00 +VAT (non-members)

If you have any questions please contact CIPA on [email protected]

If you would like to sponsor any of our conferences, please check our sponsorship page for more information.


Members, Non Members

Programme & Speakers

The CIPA Life Sciences Conference is the UK’s premier annual educational and networking event for patent and IP professionals active in the pharma, medical technology and biotechnology sectors. Over more than two decades the Conference has provided unrivalled expert insight into the latest developments in patents, regulatory and IP law in the global life science industry. Most importantly, the event provides a friendly environment for in-house and private practice professionals to network and share experiences.

*NB: timings are approximate and are subject to change. This programme will be updated as timings, speakers and topics are confirmed.

Programme on Monday 28 November 2022

  • 09:00 - 09:30 - Registration & Coffee
  • 09:30 - 09:45 - Introduction & Welcome
    Simon Wright, Schlich Ltd

    Simon Wright, Schlich Ltd

    Simon has a Chemistry (with Biochemistry) degree from Bristol University and qualified as a UK patent attorney in 1990. He became a European Patent Attorney in 1992 while with Kilburn & Strode and joined J A Kemp in 1994. He became a partner in J A Kemp’s biotechnology group in 2005 and moved to Schlich on the south coast in January 2022.

    Simon handles patent (and trade mark) work in a wide variety of life science, chemical and pharma fields, including stem cells, human genes and genomics, drug delivery systems, contrast agents, GM crops, algae technology and CRISPR technology. He also handles mechanical work ranging from drones to electric vehicle charging. He works for a broad variety of clients ranging from individuals, SMEs and private clients up to UK universities and biotechnology start-ups. He also acts for EU and US genomics and academic institutions.

    Simon has chaired CIPA’s Life Sciences Committee for 20 years, and now also Chairs the epi Biotech committee and the UNION biotech committees. He is a member of CIPA’s Council, Patents Committee and International Liaison Committee. He is a member of epi Council and the By-Laws committee and has been selected to be a member of SACEPO. He enjoys wine, gigs, playing the sax, running and cycling.

  • 09:45 - 11:15 - UPC update
  • Background and The Current Status of UPC
    Kevin Mooney, Simmons & Simmons

    Kevin Mooney, Simmons & Simmons

  • UPC: View from the EU
    Andrās Kupecz, UPC

    Andrās Kupecz, UPC

    András Kupecz holds an LLM in private law from Amsterdam University and an MSc from Utrecht University with focus on molecular biology. He was active as a European patent litigator, dually qualified as a lawyer and a European patent attorney, before taking up his duties at the UPC.

  • UPC: Getting Ready – Life in a Small Biotech
    Susan Chiappenelli, GSK

    Susan Chiappenelli, GSK

    Susan began working at GSK in 1998 as a patent trainee.  Since then she’s worked in various IP roles across the company supporting small and large molecules, vaccines and technologies.  Having spent the 2018 – 2022 leading the team that provides IP support to the Pharmaceutical portfolio, she moved teams at the beginning of 2023 to perform the same role for the Vaccines part of the business.

    Marcus Dalton, CureVac AG

    Marcus Dalton, CureVac AG

    Marcus is a European and UK patent attorney with over 35 years experience  mainly in the pharmaceutical industry.  Marcus was formerly Vice-President & Global Head of Patents for GSK vaccine a position he held for 20 years and is now Vice- President of IP at CureVac IP a clinical stage Biopharmaceutical company. During his career Marcus has built, with his teams, global IP portfolios through partnerships, through home grown IP and strategic in licensing and out licensing of rights and has leveraged such rights including via litigation to obtain business results that enable products to come to market.

  • UPC and Unitary Patent: What should you be doing now?
    Hazel Ford, Mathys & Squire

    Hazel Ford, Mathys & Squire

    Hazel has extensive experience advising clients on all aspects of patent strategy, patent drafting, and global patent prosecution in the fields of biotechnology and pharmaceuticals. She also has substantial experience with EPO opposition and appeal proceedings, across technologies including antibodies, protein and antibody purification, therapeutics, biofuels, and drug delivery formulations. Hazel has been repeatedly ranked as an IP Star in the Managing Intellectual Property World IP Survey, and a ‘Recommended Individual’ for her expertise in the fields of pharma and biotechnology in JUVE Patent‘s Rankings UK

  • 11:15 - 11:45 - Refreshment Break
  • 11:45 - 13:00 - Update from the Patent Offices:
  • Update from the UK IPO
    Julyan Elbro, IPO

    Julyan Elbro, IPO

    Julyan Elbro is Divisional Director in charge of Patent Examination in the Intellectual Property Office, with overall responsibility for the patents service.  .  With an academic background in mathematics and computer science, he has worked at the Intellectual Property Office since 1998, originally as a Patent Examiner, but also spending some time in the Office’s Policy Directorate covering a range of portfolios including biotechnology, pharmaceuticals, and the World Trade Organisation TRIPs Agreement.  He returned to patent examining in 2006 as head of the group dealing with computing inventions, before moving to his current position in June 2009.

  • EPO: Internal Views
  • EPO: External Views
    Christopher Rennie-Smith, European patent consultant

    Christopher Rennie-Smith, European patent consultant

    After studying at Cambridge and the Vrije Universiteit, Amsterdam, Christopher lectured at Sheffield University for four years, qualified as a solicitor in 1978, and then practised intellectual property litigation in London. He was appointed a member of the Boards of Appeal at the European Patent Office in 1999, becoming a member of the Enlarged Board of Appeal in 2005 and chairman of a biotechnology technical board in 2010. He was chairman or member in hundreds of EPO appeal cases and, since 2007, many petitions for review. He was also one of the draftsmen of the 2003 Rules of Procedure of the Boards of Appeal.

    Christopher has lectured regularly on patent law since 2001 and from 2007 onwards was also involved in judicial training for both new members of the Boards of Appeal and judges from European national courts. Since retiring from the Boards of Appeal in 2014 he has remained actively involved in teaching and training in patent law and procedure and has been a visiting lecturer at Cambridge and Uppsala universities. However, his principal activity (apart from retirement) is advising as a consultant on all aspects of European patents and procedure.

    He is an Overseas Member of CIPA and one of the tutors on CIPA’s EPO Proceedings course. As well as English, he speaks fluent French and German and passable Swedish.

  • 13:00 - 14:15 - Lunch Break
  • Chair
    Dev Crease, Keltie

    Dev Crease, Keltie

  • 14:15 - 15:15 - UPC Update Continued
  • Panel discussion with UK IPO and EPO speakers
    Lawrence Cullen, Lawrence Cullen IP Consulting

    Lawrence Cullen, Lawrence Cullen IP Consulting

    Dr Lawrence Cullen was a Deputy Director at the Intellectual Property Office (IPO) in the UK from 2007 to 2024 where he had responsibility for operational delivery of Supplementary Protection Certificates (SPCs). He has recently left this role to establish his own consultancy and to develop his interests further in the role and relevance of SPCs. Dr Cullen joined the IPO in 1997 as a patent examiner in the chemistry field and worked in a variety of operational, technical and policy roles in patents and trademarks before taking on the Deputy Director role. He has extensive experience working in the area of pharma and biotech patents as well as SPCs. Dr Cullen has a wide experience as a hearing officer dealing with questions of validity. He has been directly involved in over 50 patent and over 25 SPC cases before the IPO, the UK courts and, prior to 2021, the Court of Justice of the European Union (CJEU). He has also worked as a hearing officer dealing with trade-mark disputes. Dr Cullen was educated in chemistry in Ireland and the UK and worked as a research
    scientist at various universities in Europe and USA before joining the IPO.

    Julyan Elbro, IPO

    Julyan Elbro, IPO

    Julyan Elbro is Divisional Director in charge of Patent Examination in the Intellectual Property Office, with overall responsibility for the patents service.  .  With an academic background in mathematics and computer science, he has worked at the Intellectual Property Office since 1998, originally as a Patent Examiner, but also spending some time in the Office’s Policy Directorate covering a range of portfolios including biotechnology, pharmaceuticals, and the World Trade Organisation TRIPs Agreement.  He returned to patent examining in 2006 as head of the group dealing with computing inventions, before moving to his current position in June 2009.

  • 15:15 - 15:45 - Refreshment Break
  • 15:45 - 16:35 - Bioinformatics, Machine Learning and AI: Finding a Path to Therapy in Complex Biological Data
    Camille Terfve, Mewburn Ellis

    Camille Terfve, Mewburn Ellis

    Camille is a partner in Mewburn Ellis’s Cambridge office, working at the interface between the firm’s Life Sciences and Engineering teams. Camille’s practice focuses on bioinformatics / computational biology, precision medicine, digital health, medical devices and bioengineering.

    She has particular experience in drafting and prosecuting applications related to computer-implemented inventions in the life sciences including applications of data science, simulation, machine learning and AI from biologics discovery to production, diagnostics and patient monitoring. She is a frequent contributor to the Mewburn Ellis blog, where she discusses scientific, societal, legal and ethical issues associated with life sciences in the data-driven era. She is passionate about data and analyses patent data in her spare time.

    She has a PhD in Bioinformatics from the University of Cambridge, and Master’s in Computational Biology and Bioengineering from the Universities of Cambridge and Brussels, respectively.


    Liz Elmhirst, Achilles

    Liz Elmhirst, Achilles

    Liz serves as VP Intellectual Property at Achilles Therapeutics, a Biotech company developing precision T cell therapies targeting clonal neoantigens. She has over 20 years’ experience as a patent attorney in both industry and private practice. Liz joined Achilles from D Young & Co, where she was a Senior Associate specialising in biotech patent work. Prior to that, Liz spent 9 years as Patent Counsel at GSK supporting the Vaccines business unit, with responsibility for a number of viral, bacterial and therapeutic vaccine projects and commercial products. Liz began her career in the Biotechnology and Life Sciences group at J A Kemp & Co where she qualified as a European and UK Chartered patent attorney. She has a MBiochem in Biochemistry and a MSc in Neuroscience from Oxford University. Liz is also a member of the EQE Examination Committee EC-I (A/B).

  • 16:35 - 17:30 - Scientific Presentation: On the Verge of Impossibility: Caring for All Permutations of Comorbidities Influencing Fate of Drugs in Special Populations
    Prof Amin Rostami, University of Manchester

    Prof Amin Rostami, University of Manchester

    Professor of Systems Pharmacology and Director of Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, UK & Chief Scientific Officer at Certara, Princeton, USA

    The Institute of Scientific Information (ISI, Clativate) listed Amin as one of the world’s most highly cited researchers (under ‘Pharmacology & Toxicology’) in 2017. Amin is also at 0.06% top rank of the Highly Cited Researchers List by Elsevier for pharmacology (2020). He has published over 300 peer reviewed highly influential scientific articles (>20,000
    citations, h-index = 77). The work of Professor Rostami covers wide areas of drug development over the last 30 years, ranging from pharmaceuticals (e.g. bioequivalence) to clinical pharmacology (e.g. mixture pharmacology of drug/metabolites),
    translational and systems pharmacology (e.g. quantitative proteomics of enzymes and transporter for in vitro to in vivo (IVIVE) scaling).

    Amin was co-founder of two spin-off companies from the University of Sheffield (Simcyp Limited and Diurnal PLC). As a leader in the field of physiologically-based pharmacokinetics (PBPK) and quantitative systems pharmacology (QSP), he is internationally recognized for his expertise in IVIVE to predict the behaviour of drugs in human body and understanding the associated inter-individual variabilities. He was one of the founding editors of Pharmacometrics and System Pharmacology, and
    serves on the Editorial Boards of several other journals.  As the Senior Vice President of Research & Development (SVP) and Chief Scientific Officer at Certara, he facilitates the incorporation and integration of the latest advances in translational modelling to biosimulation platforms offered by Certara to its clients, with the aim of accelerating the development and regulatory approval of safer drug products and bringing them to the patients

  • 18:15 -19:00 - Pre-dinner Drinks
  • 19:00 - 19:30 - Pre-dinner Speech
    Mr Justice Mellor

    Mr Justice Mellor

    James grew up in Sutton Coldfield, attending an independent boarding school in Rugby before going on to read Engineering and then Production Engineering at Cambridge. James worked overseas in various engineering roles before, during and after University including in Somalia, the Congo, Germany, Iraq and France before embarking on a law conversion course back at Cambridge.

    Called to the bar in 1986, James specialised in all aspects of intellectual property law, and he has also acted in contractual disputes with technical or scientific aspects including some international arbitrations.

    He has appeared in the Court of Justice of the European Union in a number of references concerned with copyright, database rights and Trade Marks, and since 1994 James has edited the leading practitioners’ text on Trade Marks.

    He was appointed as a Queen’s Counsel in 2006. James was a member of the Disability Panel of the Bar Council 1999-2005. He was appointed as Chairman of the Second Appeal Panel of the Veteran Car Club of Great Britain in 2004, as an Appointed Person for Trade Marks and Designs in 2015 and as a Deputy High Court Judge in 2020.

  • 19:30 - Dinner

Programme on Tuesday 29 November 2022

  • 09:00 - 09:05 - Introduction & Welcome
    Kristina Cornish, European and UK Patent Attorney (with IP litigator)

    Kristina Cornish, European and UK Patent Attorney (with IP litigator)

    A biotechnology and life sciences patent attorney specialist, with over 30 years in the profession.
    Recognised in professional directories each year since 2009, including Chambers and Partners, IAM 300 Strategy, IAM 10000, Managing IP and Legal 500.

    Since 2003, member of the EPO Qualifying Examination Committee (Opposition paper) and member of the CIPA Life Sciences Committee; member of the UK BIA IP Committee from 2004-2022; member of the Law Society Brexit committee (invitational) from 2016-2017.

    Invited presentations at events such as BIO (USA), C5, The American Conference, the BIA, the CIPA and the EPO; private webinars including the subjects of SPCs, priority and inventive step. Various written articles and contributions to the BIA and the CIPA Life Sciences Committees, including contributions to amicus brief submissions. Written input on biotech inventions to the latest edition of the CIPA Black Book (the CIPA Guide to the Patents Act). Invited panellist to EPO iLearn session: oppositions (June 2022).

    Until January 2022, a partner (for 20 years) in a London-based top-ranking Patent and Trademark attorney firm.

  • 09:10 - 10:25
  • US Case Law Update
    Drew Hissong, Wenderoth, Lind & Ponack

    Drew Hissong, Wenderoth, Lind & Ponack

    Partner and Co-Chair of the Chemical, Biotechnology & Pharmaceutical Group, Wenderoth, Lind & Ponack, Washington D.C.

    J.D. 1999, Case Western University School of Law, Cleveland, Ohio

    Ph.D. 1998, Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

  • Divide and Conquer: Implementing an International Divisional Filing Strategy
    Andrew Teuten, Sagittarius IP

    Andrew Teuten, Sagittarius IP

    Andrew has been a patent attorney for more than 30 years and is Senior Partner at Sagittarius IP.

    By background a graduate in natural sciences (majoring in organic chemistry) with a doctorate in protein science, Andrew started his patent career working in-house in the pharma industry. He trained as a patent attorney at Fisons (now Sanofi), then progressed to Astra (now AstraZeneca), Glaxo Wellcome and finally GlaxoSmithKline (GSK). After 10 years of in-house experience, he moved into private practice by founding Sagittarius IP. Twenty years later, Sagittarius IP is a full-service patent law firm specialising in advising clients in the life sciences area and is ranked by the Financial Times as one of Europe’s leading patent law firms. Current clients include many small privately financed biotech firms, big-pharma corporations and venture capital firms.

    Andrew has experience in all aspects of biotechnology, chemical and pharmaceutical patent practice including patent filing strategy, patent drafting, prosecution and enforcement. His subject matter specialisms include medicinal chemistry, formulation of small and large molecules, antibody technology, T-cell receptors, vaccines, therapeutic proteins and nucleic acids, inhaled medicines and diagnostics. He is expert in understanding regulatory based exclusivity periods for pharmaceutical products. He also specialises in handling IP due diligence and related contract issues associated with licence agreements or investments. He has experience of multinational litigation, principally gained in USA, Japan, France, South Africa and the UK, and has particular experience in handling EPO oppositions and appeals.

    Andrew has an active interest in IP education and training and is a former member of CIPA’s Education Committee.

  • 10:25 - 11:00 - Refreshment Break
  • 11:00 - 13:05
  • UK Law Update
    Duncan Bull, Kilburn and Strode

    Duncan Bull, Kilburn and Strode

    Duncan is a UK and European patent attorney with Kilburn & Strode and has extensive experience of coordinating large portfolios across multiple jurisdictions. Duncan has been involved with a number of contentious patent matters, including defence of a key patent covering a blockbuster drug against a large, multi-party EPO opposition. He has also been involved in a number of due diligence and freedom-to-operate projects for both large and small companies.

    Duncan has been closely involved with developing the IP strategy of several small biotech firms, including the drafting and prosecution of a number of second medical use patents, and particularly enjoys helping clients to understand and overcome challenges in the patent system. Duncan’s day-to-day workload includes areas such as antibodies, vaccines, protein-based therapeutics, biomarker diagnostics, formulations and certain medical devices.

    Duncan graduated with an MSci in Natural Sciences (Biochemistry) from Christ’s College, University of Cambridge before going on to complete a PhD at the MRC London Institute of Medical Sciences. Duncan joined the patent profession in 2014.

  • EP Law Update
    Lee Chapman, Greaves & Brewster

    Lee Chapman, Greaves & Brewster

    Lee joined Greaves Brewster in 2021 as a Director specialising in biological and life science technologies, especially advanced cell and gene therapies. He is a Chartered UK Patent Attorney, a European Patent Attorney, and a Higher Courts Patent Attorney Litigator. He has a degree in Physiological Sciences and a DPhil in Reproductive Endocrinology, both from the University of Oxford.

    Lee moved to Greaves Brewster from the UK Biotech company, Celixir, where he was the Global Head of Discovery Science and Intellectual Property. He was not only primarily responsible for all IP strategy and management but also for discovering advanced therapies for serious diseases, especially heart disease and cancer, and supporting the pre-clinical development, manufacturing, and regulatory parts of the business. He enjoys leveraging his unique in-house experience to provide clients with tailored and pragmatic IP solutions, including insightful advice on how best to develop a complete IP portfolio that meets the needs of shareholders, Board members, potential investors, and collaborators, and how IP most appropriately fits within a company’s drug development plan.

    Lee started his career at another private practice firm where he became a Partner and handled a variety of biological and life science subject matters. He has particular expertise in genes, proteins, gene and viral therapies, cell therapies, regenerative medicine, stem cells, therapeutic cloning, neurological diseases, molecular biology, CRISPR, multiplex assays and diagnostics, and nucleic acid sequencing, especially nanopore sequencing.

  • CRISPR update from the US
    Thomas Kowalski, Duane Morris LLP

    Thomas Kowalski, Duane Morris LLP

    Thomas J. Kowalski is a partner in the New York Broadway office of the US-based, global law firm, Duane Morris LLP.

    He is Chair of the Life Sciences, Pharmaceuticals, and Biotechnology Division of the firm’s Intellectual Property Practice Group and is a member of the firm’s Life Sciences group.  Tom is a Registered US Patent Attorney with over 35 years’ experience.

    Tom’s practice includes domestic and worldwide biotech, chemical and medical apparatus litigation or contentious matters, patent prosecution, and counseling; and procuring and enforcing trademarks, domestically and worldwide. He also negotiates and drafts agreements, including as to IP licensing, collaborations, and in avoidance of litigation. His counseling activities include strategies for clients to enjoy Freedom to Operate, and effecting those strategies.

    Tom earned an American Chemistry Society (ACS) certified B.S. from New York University and a J.D., with honors, from St. John’s University School of Law.

    In fulfilling the requirements for ACS certification of his NYU degree, Tom extensively studied graduate biochemistry, graduate inorganic chemistry, genetics, and computer science and performed laboratory research: a joint project amongst NYU – in the laboratory of Prof. Yorke E. Rhodes, Ph.D. – and Columbia University and The NASA Goddard Institute for Space Studies, under Carl A. Gottlieb, Ph.D.

    Also, while studying at NYU, he was awarded a National Science Foundation Undergraduate Research Participant (NSF-URP) Grant, and performed laboratory research under that Grant at Hunter College, City University of New York, in the laboratory of Prof. Joseph J. Dannenberg, Ph.D.  Tom’s work under the NSF-URP Grant was published in the Journal of Organic Chemistry.

    Tom’s professional activities have included being a member of editorial boards, and acting as an editorial advisor.  He is a member of a number of IP professional organizations, and is currently Chair of the American Bar Association’s Intellectual Property Law Pro Bono Committee.

    Tom has represented clients in numerous matters before various US Federal Courts, and the USPTO, including before the USPTO PTAB. Tom also has extensive international experience and has appeared before courts and in proceedings throughout the world, including in London, England; The Hague, Netherlands; Dusseldorf, Mannheim and Munich, Germany; Vienna, Austria; Tokyo, Japan; Melbourne and Canberra, Australia; New Zealand, and Rio de Janeiro, Brazil.

  • CRISPR EU Licensing considerations
    Kam Dhalwali, KamTec LifeScience Partners Ltd

    Kam Dhalwali, KamTec LifeScience Partners Ltd

    Kam is a builder of biotech companies through the evangelising of new impactful technology, establishing the required key cornerstone commercial partnerships required that help lay the commercial foundations and part investor. He has more than 28 years of international business development and commercial management experience and has been involved in technology &
    asset licensing with a focus on drug discovery technology platforms as well as establishing Pharma partnerships in CNS, Oncology, Cardiovascular and Metabolic Diseases.

    Prior to setting up his own consulting company in 2017, he previously led the Commercial team at Horizon Discovery plc joining in 2011 and was responsible for business growth pre and post the company’s LSE listing in 2014. At Horizon he helped formulate the CRISPR IP strategy that allowed the company to navigate the IP landscape successfully allowing Horizon to become the first commercial organisation to pioneer and successfully commercialise the technology.
    Subsequently, he has advised numerous Pharma, biotech’s, CROs and Product based companies in the Life science sector to license CRISPR technology.

    He also held a senior commercial role at Evotec AG for 10 years, where he was responsible for integrated drug discovery services throughout Europe and was formerly Head of European Commercial Development at TTP LabTech (a subsidiary of The Technology Partnership). He’s also established commercial operations and sales channels in the fields of molecular diagnostics,
    NGS workflows, and growth factors for CHO-based biopharmaceutical production.

    More recently Kam has helped raise a successful Series A and Series B round for bit.bio and helped build out the commercial organisation as well as execute on key partnerships deals. Through his own consulting company, Kamtec LifeScience Partners, he continues to follow his passions of CRISPR technology, the role of machine learning /AI in drug discovery and stem
    cells and worked with numerous companies at the C-suite level including the senior leadership of Allcyte and prepared the groundwork for their acquisition in 2021 by Exscientia.

  • 13:05 - 14:15 - Lunch / Conference ends


  • Silver Sponsor - Patent Seekers

    Patent Seekers Ltd provides research services and software solutions to Patent Professionals, Industry and Research Institutions to transform the quality and cost of research across the Patent lifecycle

    • Have Confidence in Outsourcing Your Searches
    • Developed an excellent reputation with over 17 years’ experience in the industry.
    • Trusted by clients Worldwide, including the UK, Europe, Canada, USA, Australia, Singapore, Hong Kong, China and Japan.
    • Regularly work on large scale Infringement, Invalidity and Mapping/Landscape cases.
    • Highly trained, dynamic in-house teams
    • Specialising in a wide range of subject matter
    • Training program developed by former IPO Examiners
    • Discuss your enquiry with our search team
  • Bronze Sponsor - John Venn & Sons

    John Venn & Sons is a firm of notaries and translators

    • multilingual notarial services at scale for legal advisors and multinationals with large in-house teams
    • in business for about 200 years
    • offices in London and Birmingham
    • common languages offered in-house or through experienced technical and legal translators
    • corporate member of the Institute of Translation & Interpreting
    • apostille or consular legalisation services arranged by staff couriers
  • Silver Sponsor - Sun IP

    Sun IP provides high-quality, specialised IP and translation services to meet diverse, deadline-driven, and complex prosecution and litigation needs. Our industry-leading, reliable solutions are reinforced by cutting-edge technology, a proven quality assurance process, and unparalleled customer service. Each translation project is overseen and translated by operations professionals and industry-specific experts. Our areas of expertise include PCT National Filings, EP Validations, Patent Annuities, Intellectual Property Litigation, International Arbitration, International Trade, Antitrust, Corporate Litigation, and Mergers & Acquisitions. With teams in UK, Europe and US, we pride ourselves in delivering for our customers worldwide.

The event has been added to your basket:

CIPA Life Science Conference 2022 – Manchester

Proceed to basket

Shopping Basket

No products in the cart.

Are you a CIPA member?

Sign in to your account to register for the event

Forgotten password?

If you are not yet registered or a member of CIPA, please register here

Skip to content